U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion ...

Pfizer Inc. has secured an exclusive global licensing agreement with 3SBio, Inc., a leading Chinese biopharma, for SSGJ-707.

The deal comes three months after Pfizer inked a PD-1/VEGF partnership with Summit Therapeutics, leading BMO Capital Markets ...

The largest Chinese licensing deal behind Pfizer’s is Novartis’ partnership with Shanghai Argo Biopharma, worth potentially ...

Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a ...

Pfizer Inc. announced Monday it has secured exclusive global rights, excluding China, to 3SBio Inc.'s bispecific antibody ...

Pfizer's reported interest in acquiring sickle cell disease specialist Global Blood Therapeutics ... If those results are positive the partners have said they could file for approval in the ...

we are committed to accelerating the availability of global innovations while fostering partnerships with governments, healthcare providers, and key stakeholders,” Serhat Yalcinkaya, Pfizer Gulf ...

Sangamo Therapeutics’ stock has plummeted by 50% in premarket trading after Pfizer ended the companies’ partnership to co ... s decision to terminate their global collaboration and license ...

and global Pfizer RWE leaders to explore the potential of Abu Dhabi’s Trusted Research Environment in advancing scientific discovery. This initiative is part of a broader effort under the MoU to ...

“We do not see low-hanging fruit to boost shareholder value,” David Risinger, a Leerink Partners ... Global Market Intelligence. Trained as a veterinarian, Bourla spent much of his career at ...

Seigerman said Pfizer could now pursue a deal or partnership in the near term. Shares of Lilly climbed 2.6%, while Novo Nordisk's Copenhagen-listed shares rose over 3%. Pfizer's shares rose about ...